Self-expanding (SE) Stent Can Outperform Balloon-expandable (BE) Stent For The Treatment Of Iliac Artery (atherosclerosis) Disease
A study at the Asklepios Klinikum Harburg, Hamburg, Germany, shows that atherosclerosis in the iliac arteries can be treated effectively with self-expanding (SE) stent compared to balloon-expandable (BE) stent. Endovascular surgery or treatments are less invasive and preferred for the treatment of aortoiliac lesions and iliac artery stenting. But there is no information which shows the best type of stent to be used in the treatments.
The researchers have conducted a study to find out an effective stent for the treatment of iliac artery (atherosclerosis) disease on 660 patients of peripheral artery disease (Rutherford stage 1 to 4) in Northern Europe (German and Switzerland) between August 2010 and June 2013.
The study shows that the self-expanding (SE) stents for the treatment of iliac artery occlusive disease may cause a decrease in restenosis (recurrence of narrowing of a blood vessel) at one year compared to balloon-expandable (BE) stents.
Restenosis in the self-expanding (SE) stent procedure is 6.1 percent compared to 14.9 percent in a balloon-expandable (BE) stent procedure. The study also shows there is no difference in walking impairment, amputation rate, hemodynamic (dynamics of blood flow) success, complications before, during or after the stent procedure or all-cause death.
The lead investigator of the study was Dr. Hans Krankenberg, Angiology, a specialist in Internal Medicine, Cardiology, Department of Angiology, Asklepios Klinikum Harburg, Hamburg, Germany. The study was published online on August 20, 2017, in the Journal of the American College of Cardiology. Title of the article was "Self-Expanding Versus Balloon-Expandable Stents for Iliac Artery Occlusive Disease: The Randomized ICE Trial."
Repairing And Self-healing Of Damaged Hearts After A Heart Attack Or Heart Failure By Preventing Singheart RNA Molecule
Researchers at the National University Health System (NUHS) and the Genome Institute of Singapore (GIS), Singapore have discovered a ribonucleic acid (RNA) molecule, named as the Singheart molecule, that prevents self-healing and repairing of the damaged heart cells in patients of heart failure or heart attack.
The researchers say that the Singheart molecule is the single-stranded equivalent of DNA and having the power to manage the other genes. The tissues of the heart do not heal as the Singheart molecule can prevent the functions of the cell such as cell division and cell regeneration.
The study shows that the heart cells of the patients of heart disease will contain a large number of Singheart molecules. They think that the heart cells of the seniors or elderly patients of heart diseases may also contain a large number of Singheart molecule.
The researchers have neutralized and blocked Singheart molecules in an experiment on mice models. The researchers have observed the regeneration, self-repairing and self-healing of heart cells. An experiment on heart attack induced adult mice model shows complete healing of the tissues of the heart within a month after injecting complementary molecules.
Skin cells have the ability to heal themselves. But heart cells are deprived of the self-healing process and suffers permanent scar due to the presence of Singheart molecule. Researchers say that there will be no effects of a heart attack if the heart cells can heal like the skin cells.
This was the first study showing an association between the RNA and heart attack or heart failure. Researchers say that they are going to conduct a human trial within the next five years.
The lead author and the principal investigator of the study was Associate Professor Roger Foo. The first author of the study was Dr. Kelvin See. The study was published on August 9, 2017, in Nature Communications. Title of the article was "Single cardiomyocyte nuclear transcriptomes reveal a lincRNA-regulated de-differentiation and cell cycle stress-response in vivo."
The Diabetes News Chronicle does not provide medical advice, diagnosis or treatment. Information in Diabetes News Chronicle is to support and not to replace medical advice given by the surgeon or physician or doctor. The published article is not a medical advice by the OWNER of the "Diabetes News Chronicle" website or by the AUTHOR of the article.
Published by Jammi Vasista, Chennai, India.